Valeant Pharma (NYSE: VRX) is recently up $1.55 to $24 in the premarket on backs FY16 revenue guidance of $9.9B-$10.1B, compared to consensus $10.01B. August weekly call option implied volatility is at 147, August is at 109, September is at 84; compared to its 52-week range of 34 to 175.